The rise of GLP-1 weight loss medications such as Mounjaro (Tirzepatide), Ozempic, Wegovy, and Rybelsus has revolutionised medical weight management. Originally developed for type 2 diabetes, these therapies are now helping thousands achieve effective, doctor-supervised weight reduction.
For anyone comparing Mounjaro vs Ozempic or other GLP-1 therapies, it’s vital to understand their benefits, side effects, and how they differ. The following guide from Holistica Health’s Weight Loss Clinic explains how each treatment works and what you should consider before starting.
Semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) mimics a natural GLP-1 hormone that regulates blood sugar and appetite.
Tirzepatide (found in Mounjaro) is a dual GLP-1 and GIP agonist, meaning it acts on two hormonal pathways. This dual mechanism makes Mounjaro one of the most powerful weight-loss options available.
👉 For clinical information, visit the Therapeutic Goods Administration (TGA) GLP-1 overview: https://www.tga.gov.au/news/safety-updates/medicines-containing-glp-1-and-dual-gipglp-1-receptor-agonists
Both medications reduce hunger, improve satiety, and promote sustainable fat loss when paired with healthy eating and physical activity.
Mechanism: Targets both GIP and GLP-1 receptors to boost insulin sensitivity and suppress appetite.
Dosage: Weekly injection starting at 2.5 mg, titrated up to 15 mg.
Effectiveness: In SURMOUNT-1 trials, patients lost up to 22 % of body weight over 72 weeks—significantly higher than Semaglutide drugs.
Approval: TGA-approved for diabetes; weight-loss indication under review (off-label use permitted under medical supervision).
For eligible patients, Mounjaro offers faster and greater weight loss than most other GLP-1 medications.
Ozempic is a weekly Semaglutide injection mainly prescribed for diabetes but widely used off-label for weight management.
Wegovy, a higher-dose version, is specifically approved for obesity and delivers stronger appetite suppression.
Ozempic: 0.25–1 mg weekly; 5–10 % average body-weight loss.
Wegovy: Titrated to 2.4 mg weekly; 10–15 % weight loss in trials.
Both medications are available in Australia, with Ozempic PBS-subsidised for diabetes and Wegovy privately available.
For patients who prefer tablets, Rybelsus offers an oral form of Semaglutide. It’s less potent but ideal for those avoiding injections.
Dosage: 3 mg–14 mg daily on an empty stomach.
Effectiveness: 5–7 % weight loss in diabetes patients.
Approval: TGA-approved for diabetes; off-label for weight loss.
| Medication | Active Ingredient | Use | Form | Average Weight Loss | Australia Approval |
|---|---|---|---|---|---|
| Mounjaro | Tirzepatide | Diabetes, off-label for weight loss | Weekly injection | 20–22 % | Approved for diabetes |
| Wegovy | Semaglutide | Obesity treatment | Weekly injection | 10–15 % | Approved for weight loss |
| Ozempic | Semaglutide | Diabetes, off-label weight loss | Weekly injection | 5–10 % | Approved for diabetes |
| Rybelsus | Semaglutide | Diabetes | Daily tablet | 5–7 % | Approved for diabetes |
Common side effects include:
Nausea, bloating, or diarrhoea
Fatigue or headaches
Constipation during dose escalation
Rarely: pancreatitis or gallbladder inflammation
Most symptoms improve over time. Always consult a Holistica Health GP before starting or adjusting any GLP-1 medication: https://holisticahealth.com.au/services/weight-loss-clinic/
Mounjaro offers the strongest overall results for patients with metabolic issues or insulin resistance.
Wegovy is ideal for approved obesity management under clinical supervision.
Ozempic suits diabetic patients seeking moderate weight loss.
Rybelsus provides a convenient, needle-free alternative.
GLP-1 weight loss medications—Mounjaro, Wegovy, Ozempic, and Rybelsus—represent a major advancement in medical weight management. Choosing the right option depends on your goals, health background, and affordability.
Speak with your GP or Nurse Practitioner to determine which treatment suits you best.
For more scientific insight, explore the TGA’s GLP-1 resource for official Australian guidance.